P
Philip Z Brohawn
Researcher at AstraZeneca
Publications - 8
Citations - 1073
Philip Z Brohawn is an academic researcher from AstraZeneca. The author has contributed to research in topics: Durvalumab & Anifrolumab. The author has an hindex of 7, co-authored 8 publications receiving 483 citations.
Papers
More filters
Journal ArticleDOI
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Eric F Morand,Richard Furie,Yoshiya Tanaka,Ian N. Bruce,Anca Askanase,Christophe Richez,Sang Cheol Bae,Philip Z Brohawn,Lilia Pineda,Anna Berglind,Raj Tummala,Tulip Trial Investigators +11 more
TL;DR: Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a significant effect as discussed by the authors.
Journal ArticleDOI
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
Richard Furie,Eric F Morand,Ian N. Bruce,Susan Manzi,Kenneth C. Kalunian,Edward M Vital,Theresa Lawrence Ford,Ramesh Gupta,Falk Hiepe,Mittermayer Barreto Santiago,Philip Z Brohawn,Anna Berglind,Raj Tummala +12 more
TL;DR: The efficacy of anifrolumab versus placebo in a phase 3 trial of adult patients with SLE and moderate-to-severe disease activity despite standard-of-care treatment was confirmed, and other measures of disease activity were assessed, including the British Isles Lupus Assessment Group-based composite lupus assessment (BICLA).
Journal ArticleDOI
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.
Ronan J. Kelly,Ronan J. Kelly,Jeeyun Lee,Yung-Jue Bang,Khaldoun Almhanna,Mariela Blum-Murphy,Daniel V.T. Catenacci,Hyun Cheol Chung,Zev A. Wainberg,Michael K. Gibson,Keun Wook Lee,Johanna C. Bendell,Crystal S. Denlinger,Cheng Ean Chee,Takeshi Omori,Rom Leidner,Heinz-Josef Lenz,Yee Chao,Marlon Rebelatto,Philip Z Brohawn,Peng He,Jennifer McDevitt,Siddharth Sheth,Siddharth Sheth,Judson M. Englert,Geoffrey Y. Ku +25 more
TL;DR: In this article, a randomized, multicenter, open-label, phase Ib/II study assessed durvalumab and tremelimumab in combination or as monotherapy for chemotherapy-refractory gastric cancer or gastroesophageal junction (GEJ) cancer.
Journal ArticleDOI
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study
Han Si,M. Kuziora,Katie Quinn,Elena Helman,Jiabu Ye,F. Liu,U. Scheuring,Solange Peters,Naiyer A. Rizvi,Philip Z Brohawn,Koustubh Ranade,Brandon Higgs,Kimberly C. Banks,Vikram Chand,Rajiv Raja +14 more
TL;DR: In this article, the authors used the GuardantOMNI ctDNA platform for quantifying tumor mutational burden (TMB) in the blood of patients with non-small cell lung cancer.
Journal ArticleDOI
15LBA High tumoral IFNγ mRNA, PD-L1 protein, and combined IFNγ mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients
Brandon Higgs,Paul B. Robbins,J.A. Blake-Haskins,Wei Zhu,Chris Morehouse,Philip Z Brohawn,Marlon Rebelatto,Y. Yao,X. Jin,L. Shi,Koustubh Ranade +10 more